Immunotherapy innovation: myNEO Therapeutics’ Cedric Bogaert

Introducing Cedric

Cedric kindly explains that he co-founded myNEO several years ago and continues to serve as CEO.  myNEO combines “expertise from different academic institutions“.

What is myNeo’s approach?

myNEO may be relatively young, but the approach the team is taking seems to work! We asked Cedric about their efforts and what sets them apart from others’.

“We try to identify what is going on within the tumour, how it interacts with the immune system, and how we can make sure that the interplay between the two is optimised.”

This involves making sure the immune system can “recognise” the tumour, equipping it with the “proper targets”. To approach this challenge, the team at myNEO takes a “very extensive approach”.

“We start from whole genome sequencing material, that means we generate a lot of data, and then we apply big data learnings, machine learning, AI, to be able to investigate what’s going on within that tumour, which targets are relevant to that tumour, not only looking at the surface targets but really looking at everything going on within the tumour, and based on that we apply a lot of selection criteria to identify these are the best targets’.”
Data, data, data

Cedric mentioned “a lot of data” in his previous answer, so we asked about how this is drawn and developed so quickly, and why this is important. He explains that, through a collaboration with Amazon, every time a patient joins the platform their data is efficiently generated, analysed, and then reported in a matter of days. Cedric describes their system as a “nice, interactive way of playing with data” to produce results.

“We’re very flexible in the way that we can analyse hundreds of patients at the same time.”

This is so important because everyone, from pharma to patient, is “waiting on the results”.

“When looking at personalised analysis, and each patient’s treatment is dependent on the analysis that we do, then we need to have it as soon as possible.”
Partnerships

Cedric refers to partners, so how important is it that he and his team is able to secure and sustain good relationships? He reflects that “we’re a technology player”, with a “unique” platform. Therefore, they need to get this “state-of-the-art” technology to patients “as soon as possible”.

“We cannot do everything ourselves, right; we need to find the best partners that allow us and enable us to bring that into the patients.”

In the past, these partnerships have involved everyone from “big pharma” to academics. However, the team has recently had some “developments” with “good data”, which has allowed them to shift into some of their own clinical programmes. They are now collaborating with a “different set of partners”: CDMOs and CROs, for example.

What does the future hold?

With this recent change in mind, we asked about the future of myNEO. Cedric comments that his organisation is “shifting” to become a drug development company: “it’s very nice”! He suggests that this is complemented by changes in “expertise” within the board.

“So far all the clinical data has been very promising, so we’re looking forward to that future of actually, not only being being dependent on other players bringing our technology to the patients, but actually pushing for it ourselves.”
Why WVC?

As always, we invited Cedric to share his hopes for the Congress. He was looking forward to connecting with existing and future partners in person.

“You know, it’s always more interesting to have a physical conversation like we are having, than to have it via teams or zoom call.”

We hope Cedric was able to make the most of this opportunity!

External Links

Company Website

More news on MyNEO

myNEO Therapeutic’s CEO Cedric Bogaert receives Medical Genetics award at the Vatican!

myNEO Therapeutic’s CEO Cedric Bogaert receives Medical Genetics award at the Vatican!

Read more

Start-up myNEO ontwikkelt gepersonaliseerde kankervaccins

Start-up myNEO ontwikkelt gepersonaliseerde kankervaccins

Read more

Gentse biotechspeler myNEO gaat kanker te lijf met gepersonaliseerd vaccin

Gentse biotechspeler myNEO gaat kanker te lijf met gepersonaliseerd vaccin

Read more

Fighting Cancer with Personalized Vaccines: OncoDNA and myNEO Join Forces to Unlock the Power of mRNA Therapeutics

Fighting Cancer with Personalized Vaccines: OncoDNA and myNEO Join Forces to Unlock the Power of mRNA Therapeutics

Read more

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

Read more

More News

LA LIBRE : Sortlist lance un produit IA pour modéliser des budgets

LA LIBRE : Sortlist lance un produit IA pour modéliser des budgets

Read more

Flyx.cloud nominated for APEA awards

Flyx.cloud nominated for APEA awards

Read more

Inpulse au journal de 20h (France 2)

Inpulse au journal de 20h (France 2)

Read more

Une première mondiale belge : des implants contre l’épilepsie activés par la lumière

Une première mondiale belge : des implants contre l’épilepsie activés par la lumière

Read more

Synergia Medical Successfully Implants First Patients with NAO.VNS™

Synergia Medical Successfully Implants First Patients with NAO.VNS™

Read more

Clouds of Care Secures 5 Million Euros to Propel CNS Healthcare Innovation and appoints former CEO of Biogen, Michel Vounantsos, as chairman of the board of directors.

Clouds of Care Secures 5 Million Euros to Propel CNS Healthcare Innovation and appoints former CEO of Biogen, Michel Vounantsos, as chairman of the board of directors.

Read more

Clouds of Care helpt betere medicijnen maken met tech en data

Clouds of Care helpt betere medicijnen maken met tech en data

Read more

Cédric Volanti devient CEO d’Exothera, la filiale CDMO d’Univercells

Cédric Volanti devient CEO d’Exothera, la filiale CDMO d’Univercells

Read more

Vaxinano’s vaccine is presented in the Pairi Daiza Zoo collaboration

Vaxinano’s vaccine is presented in the Pairi Daiza Zoo collaboration

Read more

Univercells fait peau neuve pour s’adapter à son évolution

Univercells fait peau neuve pour s’adapter à son évolution

Read more

La biotech wallonne Univercells revend sa filiale Univercells Technologies pour 136 millions d’euros

La biotech wallonne Univercells revend sa filiale Univercells Technologies pour 136 millions d’euros

Read more

L’ECHO : Gedeon Richter reprend la biotech liégeoise BCI Pharma

L’ECHO : Gedeon Richter reprend la biotech liégeoise BCI Pharma

Read more

SYNERGIA published in NATURE: An optoelectronic implantable neurostimulation platform allowing full MRI safety and optical sensing and communication

SYNERGIA published in NATURE: An optoelectronic implantable neurostimulation platform allowing full MRI safety and optical sensing and communication

Read more

L’ECHO : Sortlist s’attaque à l’IT et l’IA

L’ECHO : Sortlist s’attaque à l’IT et l’IA

Read more

Univercells : la biotech wallonne s’associe à un géant du vaccin indien pour fabriquer des vaccins contre le cancer

Univercells : la biotech wallonne s’associe à un géant du vaccin indien pour fabriquer des vaccins contre le cancer

Read more

dFakto completes DataVaultAlliance’s Vendor Tool Certification Program

dFakto completes DataVaultAlliance’s Vendor Tool Certification Program

Read more

Inpulse met l’intelligence artificielle au service des restaurateurs

Inpulse met l’intelligence artificielle au service des restaurateurs

Read more

TheClubDeal becomes TCD Capital

TheClubDeal becomes TCD Capital

Read more

Hugues Bultot, CEO d’Univercells, est notre invité de ce dimanche: «Nous voulons avancer sur le traitement personnalisé du cancer»

Hugues Bultot, CEO d’Univercells, est notre invité de ce dimanche: «Nous voulons avancer sur le traitement personnalisé du cancer»

Read more

LIBRE ECHO: SORTLIST: Des start-up dans la tourmente: voici comment la pépite belge Sortlist a évité le crash en 2023

LIBRE ECHO: SORTLIST: Des start-up dans la tourmente: voici comment la pépite belge Sortlist a évité le crash en 2023

Read more

Immunotherapy innovation: myNEO Therapeutics’ Cedric Bogaert

Immunotherapy innovation: myNEO Therapeutics’ Cedric Bogaert

Read more

L’ECHO : Sortlist s’est réinventé pour atteindre la rentabilité

L’ECHO : Sortlist s’est réinventé pour atteindre la rentabilité

Read more

TCD Capital Fund II elects Marc Speeckaert as Chairman and Colette Plasman joins the Board

TCD Capital Fund II elects Marc Speeckaert as Chairman and Colette Plasman joins the Board

Read more

L’ancien couvent du Gesù reconverti en un complexe résidentiel durable, grâce au projet « Royal Botanic »

L’ancien couvent du Gesù reconverti en un complexe résidentiel durable, grâce au projet « Royal Botanic »

Read more

Univercells s’implante outre-Atlantique

Univercells s’implante outre-Atlantique

Read more

LA LIBRE : Yust, le rooftop tendance de Liège

LA LIBRE : Yust, le rooftop tendance de Liège

Read more

Inpulse lève 7 M€ et veut booster son outil d’intelligence artificielle auprès des chaînes

Inpulse lève 7 M€ et veut booster son outil d’intelligence artificielle auprès des chaînes

Read more

LA LIBRE ECO: La société anversoise Yust lève 8 millions d’euros pour développer son concept de coliving

LA LIBRE ECO: La société anversoise Yust lève 8 millions d’euros pour développer son concept de coliving

Read more

Créer de la valeur avec des valeurs

Créer de la valeur avec des valeurs

Read more

On a testé le loft urbain Yust et son rooftop avec vue imprenable sur les Guillemins

On a testé le loft urbain Yust et son rooftop avec vue imprenable sur les Guillemins

Read more

L’ECHO : TheClubDeal investit dans Flyx et sa solution de digitalisation des commandes

L’ECHO : TheClubDeal investit dans Flyx et sa solution de digitalisation des commandes

Read more

L’ECHO : Univercells va lever 100 millions d’euros 

L’ECHO : Univercells va lever 100 millions d’euros 

Read more

L’ECHO : TheClubDeal investit dans Smartflats et ses appart-hôtels

L’ECHO : TheClubDeal investit dans Smartflats et ses appart-hôtels

Read more

La Libre Belgique : Yust – un plan d’expansion sur Bruxelles puis Gand à l’horizon 2024 – du « coliving » vers le « smartliving »

La Libre Belgique : Yust – un plan d’expansion sur Bruxelles puis Gand à l’horizon 2024 – du « coliving » vers le « smartliving »

Read more

L’ECHO : Le groupe belge de maisons de repos Vivalto passe sous pavillon français

L’ECHO : Le groupe belge de maisons de repos Vivalto passe sous pavillon français

Read more

L’ECHO : BCI Pharma, la petite biotech liégeoise aux grandes ambitions

L’ECHO : BCI Pharma, la petite biotech liégeoise aux grandes ambitions

Read more

Graftys reprend la société française Biologics for Life

Graftys reprend la société française Biologics for Life

Read more

LN24 ‘Success Stories’ interviews TCD Capital

LN24 ‘Success Stories’ interviews TCD Capital

Read more

Sortlist lève 11 millions et va s’implanter en Angleterre

Sortlist lève 11 millions et va s’implanter en Angleterre

Read more

L’ECHO : Thibaut De Vylder, diriger par la donnée

L’ECHO : Thibaut De Vylder, diriger par la donnée

Read more

Fund II First Closing at 23M €

Fund II First Closing at 23M €

Read more

Risk, Return & Time in Private Equity

Risk, Return & Time in Private Equity

Read more

‘Grotere fondsen laten sterk groeiende kmo’s van links liggen’

‘Grotere fondsen laten sterk groeiende kmo’s van links liggen’

Read more

Risk, Return & Purpose

Risk, Return & Purpose

Read more

TCD Capital lance son nouveau fonds d’ancrage à 50 millions

TCD Capital lance son nouveau fonds d’ancrage à 50 millions

Read more

“Investors say Belgium’s startups are poised for international expansion”

“Investors say Belgium’s startups are poised for international expansion”

Read more

“La fintech belge attend toujours l’émergence de sa première licorne”

“La fintech belge attend toujours l’émergence de sa première licorne”

Read more

December 2020 Newsletter

December 2020 Newsletter

Read more

“Ik droom ervan weer fabrieken naar Charleroi te brengen”

“Ik droom ervan weer fabrieken naar Charleroi te brengen”

Read more

Subscribe to our Newsletter

We seek to customise the content to the segments we serve.

These are both fund investors and the entrepreneurs with whom we have created alliances.

We are happy to keep in touch.

TCD Form Template Style